Replimune Group (NASDAQ:REPL) Stock Price Up 5.5% – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL)’s stock price traded up 5.5% during trading on Wednesday . The stock traded as high as $9.70 and last traded at $9.36. 958,289 shares changed hands during trading, a decline of 80% from the average session volume of 4,806,471 shares. The stock had previously closed at $8.87.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Leerink Partners reissued a “market perform” rating and set a $2.00 target price (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. Wall Street Zen raised Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Piper Sandler cut Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a report on Friday, April 10th. Jefferies Financial Group reissued a “hold” rating and set a $2.00 target price (down from $13.00) on shares of Replimune Group in a report on Monday, April 13th. Finally, Weiss Ratings raised Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. Seven analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Replimune Group currently has an average rating of “Reduce” and a consensus price target of $4.88.

Replimune Group Price Performance

The company has a market cap of $834.78 million, a P/E ratio of -2.94 and a beta of 0.91. The company has a fifty day simple moving average of $4.92 and a 200-day simple moving average of $7.25. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60.

Insider Activity

In other Replimune Group news, insider Christopher Sarchi sold 6,500 shares of the company’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total value of $52,065.00. Following the transaction, the insider owned 151,588 shares of the company’s stock, valued at approximately $1,214,219.88. This represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fcpm Iii Services B.V. raised its stake in Replimune Group by 6.4% during the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock valued at $17,424,000 after purchasing an additional 248,672 shares during the period. Erste Asset Management GmbH raised its stake in Replimune Group by 13,597.5% during the 3rd quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock valued at $7,074,000 after purchasing an additional 1,618,100 shares during the period. Braidwell LP raised its stake in Replimune Group by 550.3% during the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after purchasing an additional 2,327,205 shares during the period. Readystate Asset Management LP raised its stake in Replimune Group by 1,296.2% during the 3rd quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after purchasing an additional 2,433,292 shares during the period. Finally, Quinn Opportunity Partners LLC acquired a new stake in Replimune Group during the 3rd quarter valued at $2,727,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.